CHAMP-HF: Heart Failure Treatment in US Remains Subpar

@media print { body { margin: 2mm 9mm; } .original-url { display: none; } #article .float.left { float: left !important; } #article .float.right { float: right !important; } #article .float { margin-top: 0 !important; margin-bottom: 0 !important; } }CHAMP-HF: Heart Failure Treatment in US Remains Subparhttps://www.medscape.com/viewarticle/899433?src=rssCHAMP-HF: Heart Failure Treatment in US Remains SubparMajor gaps remain in use and dosing of evidence-based, guideline-recommended medications for heart failure with reduced ejection fraction (HFrEF), according to a new analysis of data from the Change the Management of Patients with Heart Failure (CHAMP-HF) registry." Even in the absence of any new heart failure therapies being discovered, if the existing guideline-recommended medical therapies were optimally implemented and dosed, tens of thousands of additional deaths in patients with heart failure could be avoided each year, " senior author Gregg Fonarow, MD, University of California, Los Angeles, toldtheheart.org | Medscape Cardiology." Despite a robust database and well-articulated clinical practice guidelines, the findings from the CHAMP-HF registry demonstrate the care deficit that still needs to be addressed, " said Clyde Yancy, MD, Northwestern University Feinberg School of Medicine in Chicago, Illinois, who wasn ' t involved in the study.The study waspu...
Source: Dr Portnay - Category: Cardiology Authors: Source Type: blogs